Medication info
Empaglinide Metformin Hydrochloride Extended-Release Tablets 10/1000 mg (Empagliflozin, Metformin Hydrochloride)

Empaglinide Metformin Hydrochloride Extended-Release Tablets 10/1000 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›10mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Dongguk Pharmaceutical Co., Ltd.
Appearance
Pale pink, oval-shaped, biconvex, extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501719 · Approved 2025.07.09 · Insurance code 653406060

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin. Patients taking this drug 10/1000 mg extended-release tablets or 25/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this drug 5/1000 mg extended-release tablets or 12.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain the extended-release properties, this drug should be swallowed whole and not split, crushed, ground, or chewed. This drug may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions, 5. General Precautions). ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose when taking this drug is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate. ⦁ When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions, 4. Adverse Reactions and 6. Interactions). Special Populations Renal Impairment Because dose adjustment may be required based on renal function, assessment of renal function is recommended before starting this drug and periodically during treatment. No dosage adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this drug may be used with adjustment of the metformin hydrochloride dose as follows: - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to <45 ml/min or estimated glomerular filtration rate (eGFR) decreases to <45 ml/min/1.73m2, this drug should be discontinued immediately. Elderly Patients For patients aged 75 years and older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Dongguk Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes with difficult blood glucose control
  • cardiovascular disease
View approved original text

This medication is used in conjunction with dietary modifications and exercise to improve blood glucose control in adults with type 2 diabetes mellitus. It is especially suitable for patients whose blood glucose levels are not sufficiently controlled and should be used with caution in those with cardiovascular disease. The medication is designed to effectively assist in blood glucose management while ensuring safety in consideration of cardiovascular risks.

How to take

Adult dose

The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin. Patients taking this drug 10/1000 mg extended-release tablets or 25/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this drug 5/1000 mg extended-release tablets or 12.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain the extended-release properties, this drug should be swallowed whole and not split, crushed, ground, or chewed. This drug may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions, 5. General Precautions). ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose when taking this drug is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate. ⦁ When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions, 4. Adverse Reactions and 6. Interactions). Special Populations Renal Impairment Because dose adjustment may be required based on renal function, assessment of renal function is recommended before starting this drug and periodically during treatment. No dosage adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this drug may be used with adjustment of the metformin hydrochloride dose as follows: - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to <45 ml/min or estimated glomerular filtration rate (eGFR) decreases to <45 ml/min/1.73m2, this drug should be discontinued immediately. Elderly Patients For patients aged 75 years and older, renal function and the risk of volume depletion should be considered.

Precautions

This medication is used in the treatment of type 2 diabetes and helps control blood glucose levels. It can cause a rare side effect known as severe lactic acidosis; therefore, it should not be used in patients with renal function impairment or liver function issues. Additionally, caution is advised if taken with insulin or sulfonylurea agents due to the risk of hypoglycemia. Patients with moderate to severe renal impairment, acute infections, dehydration, heart failure, type 1 diabetes, acute or chronic metabolic acidosis should not take this medication. The medication should be temporarily discontinued before and after using iodine contrast agents during tests, and it should only be resumed after confirming normal kidney function. This medication can cause side effects such as increased urination, urinary tract infections, and genital infections, so patients should consult a doctor immediately if symptoms of infection appear. Hypoglycemic symptoms can also occur, so patients should eat regularly, and dose adjustments may be needed when used with drugs that carry a high risk of hypoglycemia. Elderly patients or those with decreased fluid volume should be closely monitored due to the risk of dehydration and hypotension. Pregnant or potentially pregnant women and nursing mothers are advised against using this medication. In cases of overdose, serious side effects such as lactic acidosis may occur, requiring immediate medical treatment, including possible dialysis. This medication should be swallowed whole without crushing or chewing, and the tablet coating may be excreted in feces, which is normal. If any unusual symptoms or suspected side effects occur during use, patients should immediately consult their healthcare provider.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased vitamin B12 and deficiency
  • ketoacidosis
  • lactic acidosis
  • decreased fluid volume
  • nausea
  • vomiting
Show 133 more
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • altered taste
  • itching
  • rash
  • urticaria
  • erythema
  • angioedema
  • difficulty urinating
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • vaginismus
  • vulvitis
  • balanitis
  • perineal necrosis
  • weight loss
  • constipation
  • gastritis
  • dry mouth
  • gastrointestinal disorders
  • oral discomfort
  • salivary gland pain
  • cerebral infarction
  • headache
  • sensory loss
  • postural dizziness
  • dizziness
  • weakness
  • chest discomfort
  • chest pain
  • fever
  • facial swelling
  • chills
  • abnormal sensations
  • edema
  • pain
  • pain at the puncture site
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • weight gain
  • abnormal electrocardiogram
  • decreased hemoglobin
  • increased hemoglobin
  • positive Helicobacter test
  • positive urine red blood cells
  • urinary stones
  • hematuria
  • renal mass
  • urinary retention
  • abnormal urine
  • vulvar pruritus
  • genital pruritus
  • dyslipidemia
  • hyperglycemia
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • eye discomfort
  • eye congestion
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • macular retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • sputum retention
  • cough
  • skin laceration
  • rib fracture
  • ligamentous strain syndrome
  • angina
  • palpitations
  • Prinzmetal's angina
  • coronary artery disease
  • tachycardia
  • arteriosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral artery obstructive disease
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • postural vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid mass
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. The storage temperature should be maintained at room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pale pink, oval-shaped, biconvex, extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.